JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

Search

CRISPR Therapeutics AG

Închisă

SectorSănătate

51.78 1.31

Rezumat

Modificarea prețului

24h

Curent

Minim

50.56

Maxim

52.78

Indicatori cheie

By Trading Economics

Venit

102M

-106M

Vânzări

-3K

889K

Marjă de profit

-11,973.116

Angajați

393

EBITDA

101M

-101M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+35.7% upside

Dividende

By Dow Jones

Următoarele câștiguri

9 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-746M

4.9B

Deschiderea anterioară

50.47

Închiderea anterioară

51.78

Sentimentul știrilor

By Acuity

10%

90%

9 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 feb. 2026, 23:11 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb. 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 feb. 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb. 2026, 23:38 UTC

Câștiguri

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb. 2026, 23:29 UTC

Achiziții, Fuziuni, Preluări

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb. 2026, 23:27 UTC

Achiziții, Fuziuni, Preluări

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb. 2026, 23:25 UTC

Achiziții, Fuziuni, Preluări

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb. 2026, 23:23 UTC

Achiziții, Fuziuni, Preluări

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb. 2026, 23:22 UTC

Achiziții, Fuziuni, Preluări

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb. 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb. 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 feb. 2026, 22:56 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb. 2026, 22:40 UTC

Câștiguri

Amdocs Extends Collaboration With T-Mobile

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q Adj EPS $1.81

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q Rev $1.16B

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q EPS $1.45 >

3 feb. 2026, 22:38 UTC

Câștiguri

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb. 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb. 2026, 22:14 UTC

Câștiguri

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb. 2026, 22:13 UTC

Câștiguri

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb. 2026, 22:12 UTC

Câștiguri

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb. 2026, 22:10 UTC

Câștiguri

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb. 2026, 22:10 UTC

Câștiguri

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb. 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb. 2026, 22:10 UTC

Câștiguri

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb. 2026, 22:09 UTC

Câștiguri

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb. 2026, 22:09 UTC

Câștiguri

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

35.7% sus

Prognoză pe 12 luni

Medie 69.63 USD  35.7%

Maxim 105 USD

Minim 40 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

11

Cumpărare

7

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

9 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat